700443Market and product profiling for diagnostics in kidney injuryClosedGRD Proof of MarketInnovate UKAcute kidney injury (AKI) causes 12,000 preventable deaths per year in England. It affects 14% of people admitted to hospital, extending their hospital stay 2.5fold (£1.2Bn cost per annum to NHS England) and increasing their chance of death 4-5fold. Better diagnostics are required to identify AKI patients early. This will permit the focusing of resources on those in greatest need, and will save lives and money. A definitive diagnostic test for “early-AKI” does not yet exist, although a number of promising biomarkers and assays are in development. The commercial opportunity create by such a diagnostic test is large, £2.25-4.5Bn per annum (1). Badrilla Ltd has identified an excellent fit between its proprietary technology (US patent 7,939,265) and the technical specifications of improved AKI diagnostic tests. Badrilla Ltd has assembled an expert team of nephrologists and technologists to create and validate new diagnostics for the early diagnosis of AKI. The first phase of our collaboration (SMART PoM) is to define the market and product profile precisely, to focus all subsequent work for maximum clinical and commercial impact. Phase 1 will review the AKI literature, segment the field carefully (primary care, secondary care, disease aetiologies and patient stratification), and integrate this with a map of the commercial and intellectual property landscape for AKI diagnostics. This will define a clear position for new diagnostic (product) development in AKI. Finally, we will conduct primary research with clinicians to refine the product profile, and, with diagnostics companies, to define the deliverables required for initiation of codevelopment partnerships. This will define the strategy and activities to deploy our technology in the medical diagnostics sector. 1. Assumptions: test price £12.50; patient population (global) 60million; tests per year per patient, 3-6.